Geroscience and Alzheimer’s Disease Drug Development

Age is the most important risk factor for Alzheimer’s disease (AD). The acceptable age range for participation in AD clinical trials is 50 to 90, and this 40-year span incorporates enormous age-related change. Clinical trial participants tend to be younger and healthier than the general population....

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The Journal of Prevention of Alzheimer's Disease 2023, Vol.10 (4), p.620-632
Hauptverfasser:	Cummings, Jeffrey, Osse, A. M. Leisgang, Kinney, J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Alzheimer Disease - drug therapy Amyloid beta-Peptides Biomarkers Drug Development Geriatrics/Gerontology Geroscience Humans Medicine Medicine & Public Health Neurology Review
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!